Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 7 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
Cancer Research Technology Limited is managing 8 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 8 distinct examiners and 7 distinct art units. This number of examiners relative to the 8 pending office actions indicates a decentralized prosecution landscape where nearly every case is handled by a different individual. The involvement of 7 distinct art units further suggests that the portfolio spans a wide range of technical sub-specialties.
LIPPERT, JOHN WILLIAM is the busiest examiner, currently handling 1 pending office action. Because there are 8 pending office actions in total, the workload is spread across the 8 distinct examiners. This lack of concentration means that no single examiner has a dominant influence over the portfolio. Practitioners must prepare for a diverse array of examiner styles, as the 7 distinct art units will likely apply varying standards of review to the Biotechnology & Pharmaceuticals subject matter.
Based on the USPTO statutory response window for each pending office action. 6 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 6 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 2 (25%) |
| §103 only | 3 (38%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 1 (12%) |
| No statute on record | 1 (12%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LIPPERT, JOHN WILLIAM | 1 | 58.2% | +40.0% |
| BATES, KEENAN ALEXANDER | 1 | 45.5% | +79.5% |
| HASTINGS, ALISON AZAR | 1 | 63.5% | +40.2% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
| LAFAVE, ELIZABETH ROSE | 1 | 62.5% | +45.4% |
| OUSPENSKI, ILIA I | 1 | 77.5% | +20.4% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 58.1% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 92d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 56d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 92d overdue |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 8d overdue |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 34d |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 40d |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 57d |
| 18682398 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | LIPPERT, JOHN WILLIAM | — |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | HASTINGS, ALISON AZAR | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 1627 | 1 |
| 1636 | 1 |
| 1637 | 1 |
| 1684 | 1 |
| 1644 | 1 |
| 1635 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682398 | DIPHOSPHINE COMPOUNDS AND COMPLEXES | LIPPERT, JOHN WILLIAM | — | §103 | Non-Final OA | — | Pending | Feb 08, 2024 |
| 18418855 | VECTOR FOR CANCER TREATMENT | BATES, KEENAN ALEXANDER | 1631 | §103§112 | Final Rejection | 92d overdue | Pending | Jan 22, 2024 |
| 18265063 | Aldehyde Dehydrogenase Inhibitors and Their Therapeutic Use | HASTINGS, ALISON AZAR | 1627 | §103 | Non-Final OA | — | Pending | Jun 02, 2023 |
| 18254324 | MEDIATORS OF GENE SILENCING | YU, DELPHINUS DOU YI | 1636 | §101§102§112Other | Non-Final OA | 56d | Pending | May 24, 2023 |
| 17911184 | Optimised Methods for Cleavage of Target Sequences | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102 | Non-Final OA | 34d | Pending | Sep 13, 2022 |
| 17781650 | SPATIAL BARCODING | LAFAVE, ELIZABETH ROSE | 1684 | §103 | Non-Final OA | 40d | Pending | Jun 01, 2022 |
| 17706028 | ANTI CD25 FC GAMMA RECEPTOR BISPECIFIC ANTIBODIES FOR TUMOR SPECIFIC CELL DEPLETION | OUSPENSKI, ILIA I | 1644 | Other | Final Rejection | 57d | Pending | Mar 28, 2022 |
| 17609691 | MEDIATORS OF GENE SILENCING | SULLIVAN, STEPHANIE LAUREN | 1635 | §112DP | Final Rejection | 8d overdue | Pending | Nov 08, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial